Jean-Jacques Bienaimé (BioMarin via Youtube)

Bio­Marin ‘turn­ing the cor­ner’ on prof­its with op­ti­mism on Vox­zo­go, Roc­ta­vian — but ques­tions re­main

Bio­Marin fi­nal­ly is ‘turn­ing the cor­ner’ on prof­itabil­i­ty in 2022, CEO Jean-Jacques Bi­en­aimé said in its earn­ings call yes­ter­day. And while in­vestors gen­er­al­ly agreed with that, they al­so have a lot of spe­cif­ic prod­uct ques­tions that Bio­Marin isn’t able to ful­ly an­swer just yet.

For in­stance, on its achon­dropla­sia drug Vox­zo­go spe­cif­ic to chil­dren in its youngest age co­hort ages 0-5, Bio­Marin de­tailed new top-line Phase II da­ta and a miss, with no sta­tis­ti­cal sig­nif­i­cance found among the young pa­tients. How­ev­er ex­ec­u­tives cau­tioned the da­ta is new, re­ceived “on­ly 24 hours ago,” and “a lit­tle com­pli­cat­ed in sig­nal and noise” dur­ing its earn­ings call Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.